Generics BulletinGlenmark expects an uptick in its key North America business beginning in the firm’s 2025/26 financial year onwards, on the back of potential launches in the respiratory and injectable segments, inclu
ScripIchnos Glenmark Innovation (IGI) has a lot at stake as it readies to present first-time data from the Phase I study of its T cell-engaging trispecific antibody (ISB 2001) at the upcoming American Soci
Pink SheetTeva has agreed to pay $425m to resolve a four-year-old US Department of Justice accusation that the firm violated the False Claims Act and the Anti-Kickback Statute by using two foundations to funne
Generics BulletinOver 50 drugs were listed in the Indian Central Drugs Standard Control Organisation’s latest ‘not of standard quality’ reports, flagging potential quality issues in widely used medicinal products in t